Printer Friendly

CIRCA LICENSES SUSTAINED RELEASE PRODUCTS FROM ANDRX CORPORATION

 COPIAGUE, N.Y., Nov. 8 /PRNewswire/ -- Circa Pharmaceuticals, Inc. (AMEX: RXC) announced today that it has entered into an exclusive licensing agreement for two generic sustained release products with Andrx Corporation's wholly owned subsidiary AndaSR Pharmaceuticals, Inc. The products will be developed jointly using technology developed by Chih Ming Chen, Ph.D., president of AndaSR. One of the sustained release products is prescription and is used in the treatment of a variety of cardiovascular conditions and the other is a generic version of a popular OTC cold and allergy remedy. Both products will require full bioequivalency testing and abbreviated new drug applications.
 Commenting on the agreements, Melvin Sharoky, M.D., president of Circa stated, "Circa is intent upon pursuing all opportunities to expand its product development and has found such an opportunity in working with AndaSR. The agreements allow us to license in this new technology and to utilize our manufacturing capabilities upon approval. We are committed to both internal and external research and development programs in meeting our goals as a diversified pharmaceutical company."
 -0- 11/8/93
 /CONTACT: Melvin Sharoky, M.D. of Circa Pharmaceuticals, Inc., 516-842-8383/
 (RXC)


CO: Circa Pharmaceuticals, Inc.; Andrx Corporation ST: New York, Florida IN: MTC SU: LIC

SS-AW -- FL004 -- 1633 11/08/93 09:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 8, 1993
Words:213
Previous Article:FORTUNE BANCORP REPORTS YEAR END EARNINGS
Next Article:KENNETH LUCAS NAMED PRESIDENT OF MADISON GROUP ASSOCIATES, INC.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters